AACR
-
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
By Kara Nyberg, PhD Posted: June 24, 2020 New findings from the TRACERx lung study underscore the value of using circulating tumor DNA (ctDNA) to predict NSCLC relapse postsurgery based […]
-
PASSION Results Support Further Study of Camrelizumab Plus Apatinib in SCLC
By Kara Nyberg, PhD Posted: June 24, 2020 The phase II PASSION trial sought to explore the potential synergy between immunotherapy and antiangiogenic drug therapy previously observed in preclinical studies. […]
-
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) […]
-
Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042 Analysis
By Kara Nyberg, PhD Posted: June 24, 2020 Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold tumor immune microenvironment in […]
-
TERAVOLT: Global Registry Investigates Outcomes Among Patients With Thoracic Cancer and COVID-19
By Marina Chiara Garassino, MD, and Leora Horn, MD, MSc, FRCPC Posted: June 9, 2020 Marina Chiara Garassino Leora Horn The new SARS-CoV-2 (COVID-19) virus […]
-
Key Findings from the CAR T-Cell Study Presented at the 2019 AACR Annual Meeting
By Prasad S. Adusumilli, MD, FACS, FCCP Posted: November 12, 2019 My colleagues and I conducted a phase I clinical trial of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy in […]
View ILCN Archives
Provider Resources